SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Who pays when an AI agent tries again?

Brandlight helps enterprise marketers manage how AI recommends their brand

BlueGreen Water Technologies turns algae blooms into large-scale carbon removal

Taboola to acquire Dianomi for up to £27 million as it pushes deeper into finance advertising

Buzz

Most popular

Daily

Weekly

1

Serbia opens Israeli drone factory as defense ties with Elbit deepen

2

The man who helped build Palo Alto’s Cortex is leaving the company

3

“Our next milestone will be a billion-dollar valuation”: MIND triples valuation to $300 million with $72 million Series B

4

How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit

5

Sayeret Matkal veterans raise $22 million to teach the world English with AI

Copaxone

4 stories about Copaxone

חברת ה תרופות טבע Teva

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer

A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer

Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug

מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich

Troubled drugmaker says new CEO must work to quickly regain its financial credibility

תרופות טבע גלולות תרופה

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian

The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016

Previous Articles